In the last trading session, 2.75 million shares of the Sangamo Therapeutics Inc (NASDAQ:SGMO) were traded, and its beta was 1.24. Most recently the company’s share price was $0.78, and it changed around -$0.01 or -1.45% from the last close, which brings the market valuation of the company to $162.62M. SGMO currently trades at a discount to its 52-week high of $1.48, offering almost -89.74% off that amount. The share price’s 52-week low was $0.29, which indicates that the current value has risen by an impressive 62.82% since then. We note from Sangamo Therapeutics Inc’s average daily trading volume that its 10-day average is 2.29 million shares, with the 3-month average coming to 14.21 million.
Sangamo Therapeutics Inc stock received a consensus recommendation rating of Buy, based on a mean score of 2.12. If we narrow it down even further, the data shows that 0 out of 6 analysts rate the stock as a Sell; another 2 rate it as Overweight. Among the rest, 1 recommended SGMO as a Hold, whereas 3 deemed it a Buy, and 0 rated it as Underweight. Sangamo Therapeutics Inc is expected to report earnings per share of -0.03 for the current quarter.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Sangamo Therapeutics Inc (NASDAQ:SGMO) trade information
Instantly SGMO has showed a red trend with a performance of -1.45% at the end of last trading. The performance over the last five days has remained in the red territory. The rise to weekly highs of 0.8961 on recent trading dayincreased the stock’s daily price by 12.96%. The company’s shares are currently up 43.75% year-to-date, but still down -9.92% over the last five days. On the other hand, Sangamo Therapeutics Inc (NASDAQ:SGMO) is 3.95% up in the 30-day period. We can see from the shorts that 17.5 million shares have been sold at a short interest cover period of 3.49 day(s).
The consensus price target as assigned by Wall Street analysts is $12, which translates to bulls needing to increase their stock price by 93.5% from its current value. Analyst projections state that SGMO is forecast to be at a low of $5 and a high of $19.
Sangamo Therapeutics Inc (SGMO) estimates and forecasts
Sangamo Therapeutics Inc share prices are performing particularly well compared to other companies within the same industry. As is evident from the statistics, the company’s shares have risen 39.17 percent over the past six months and at a 20.34% annual growth rate that is well above the industry average of 17.60%. Moreover, analysts have decided to roll up on their fiscal year 2024 revenue estimates. The rating firms predict that it will gain 94.90% in revenue this quarter, and will report an increase of 85.30% in the next quarter. The year-over-year growth rate is expected to be -69.20%, down from the previous year.
Consensus estimates provided by 7 financial analysts predict the company will bring in an average of 17.94M in revenue for the current quarter. 7 analysts expect Sangamo Therapeutics Inc to make 15.31M in revenue for the current ending quarter. The company’s sales for the same quarters a year ago were 10.4M and 2.04M respectively. Analysts predict that the company’s current quarter sales will jump, forecast at 72.50%. Forecasts for the next quarter put sales growth at 649.80%.
Looking at the company’s year-over-year earnings, the past five years showed a negative earnings growth rate of -15.96%.
SGMO Dividends
Sangamo Therapeutics Inc’s next quarterly earnings report is expected to be released in November.
Sangamo Therapeutics Inc (NASDAQ:SGMO)’s Major holders
Upon looking at major shareholders, it appears that insiders hold 2.28% of Sangamo Therapeutics Inc shares, and 42.12% of them are in the hands of institutional investors. The stock currently has a share float of 43.10%. Sangamo Therapeutics Inc stock is held by 157.0 institutions, with WASATCH ADVISORS LP being the largest institutional investor. By 2024-06-30, it held 11.1403% of the shares, which is about 20.09 million shares worth $7.2 million.
ARMISTICE CAPITAL, LLC, with 7.7963% or 14.06 million shares worth $5.04 million as of 2024-06-30, holds the second largest percentage of outstanding shares.
